v3.25.2
SEGMENT INFORMATION
6 Months Ended
Jun. 30, 2025
SEGMENT INFORMATION  
SEGMENT INFORMATION

NOTE 7 – SEGMENT INFORMATION

a.The Company operates in Israel as a single operating segment. The Company’s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.
b.Segment information:

Six Months Ended June 30, 

Three Months Ended June 30, 

(U.S. dollars in thousands)

2025

2024

2025

2024

Revenues from customers

$

25,771

$

17,222

$

15,658

$

13,474

Less:

Employee salaries and related expenses

10,649

10,357

5,444

5,213

Sub-contractors expense

7,463

4,764

4,773

2,609

Interest expense

761

379

Interest income

(528)

(757)

(272)

(374)

Depreciation

706

641

360

319

Other segment expenses*

10,552

8,461

4,692

7,600

Income (loss) before taxes on income

(3,071)

(7,005)

661

(2,272)

Taxes on income (tax benefit)

384

(207)

497

(69)

Segment net income (loss)

$

(3,455)

$

(6,798)

$

164

$

(2,203)

* Other expenses included in net income includes raw materials, rent and utilities and others.

c.The following table summarizes the Company’s disaggregation of revenues:

Six Months Ended June 30, 

Three Months Ended June 30, 

(U.S. dollars in thousands)

2025

2024

    

2025

2024

Gaucher disease:

 

Pfizer (Ireland)

$

12,626

$

8,001

$

5,647

$

6,874

Fiocruz (Brazil)

$

3,016

$

7,266

$

-

$

4,716

Fabry disease:

Chiesi (Italy)

$

9,793

$

1,714

$

9,793

$

1,714

Total revenues from selling goods

$

25,435

$

16,981

$

15,440

$

13,304

Revenues from license and R&D services

$

336

$

241

$

218

$

170

d.Long lived assets are located in Israel.